We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is Exact Sciences (EXAS) Up 45.4% Since Last Earnings Report?
Read MoreHide Full Article
It has been about a month since the last earnings report for Exact Sciences (EXAS - Free Report) . Shares have added about 45.4% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Exact Sciences due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its latest earnings report in order to get a better handle on the important drivers.
EXAS Q3 Earnings and Revenues Beat Estimates, ’25 Sales View Up
Exact Sciences Corporation (EXAS - Free Report) reported earnings per share (EPS) of 24 cents in the third quarter of 2025, beating the Zacks Consensus Estimate by 84.6%. The reported figure compares to a loss of 21 cents per share a year ago.
EXAS’ Q3 Revenues
Consolidated revenues totaled $850.7 million, up 20% on a reported as well as a core revenue basis. The figure surpassed the Zacks Consensus Estimate by 5%.
Exact Sciences’ 2025 Outlook
For full-year 2025, the company has raised its guidance for total revenues to $3.22-$3.24 billion (earlier $3.13-$3.17 billion). The Zacks Consensus Estimate is pegged at $3.23 billion.
Among these, Screening revenues are now expected to be in the range of $2.51-$2.52 billion (earlier $2.44-$2.47 billion). Precision Oncology revenues are now anticipated to be in the band of $710-$715 million (earlier $690-$700 million).
The adjusted EBITDA forecast has been updated to $470-$480 million (earlier $455-$475 million).
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in fresh estimates.
The consensus estimate has shifted -101.14% due to these changes.
VGM Scores
Currently, Exact Sciences has a strong Growth Score of A, though it is lagging a lot on the Momentum Score front with an F. Charting a somewhat similar path, the stock has a score of D on the value side, putting it in the bottom 40% for value investors.
Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Exact Sciences has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Exact Sciences belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Repligen (RGEN - Free Report) , has gained 12.3% over the past month. More than a month has passed since the company reported results for the quarter ended September 2025.
Repligen reported revenues of $188.8 million in the last reported quarter, representing a year-over-year change of +21.9%. EPS of $0.46 for the same period compares with $0.43 a year ago.
Repligen is expected to post earnings of $0.44 per share for the current quarter, representing no change from the year-ago quarter. Over the last 30 days, the Zacks Consensus Estimate has changed +0.5%.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Repligen. Also, the stock has a VGM Score of D.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Is Exact Sciences (EXAS) Up 45.4% Since Last Earnings Report?
It has been about a month since the last earnings report for Exact Sciences (EXAS - Free Report) . Shares have added about 45.4% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Exact Sciences due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its latest earnings report in order to get a better handle on the important drivers.
EXAS Q3 Earnings and Revenues Beat Estimates, ’25 Sales View Up
Exact Sciences Corporation (EXAS - Free Report) reported earnings per share (EPS) of 24 cents in the third quarter of 2025, beating the Zacks Consensus Estimate by 84.6%. The reported figure compares to a loss of 21 cents per share a year ago.
EXAS’ Q3 Revenues
Consolidated revenues totaled $850.7 million, up 20% on a reported as well as a core revenue basis. The figure surpassed the Zacks Consensus Estimate by 5%.
Exact Sciences’ 2025 Outlook
For full-year 2025, the company has raised its guidance for total revenues to $3.22-$3.24 billion (earlier $3.13-$3.17 billion). The Zacks Consensus Estimate is pegged at $3.23 billion.
Among these, Screening revenues are now expected to be in the range of $2.51-$2.52 billion (earlier $2.44-$2.47 billion). Precision Oncology revenues are now anticipated to be in the band of $710-$715 million (earlier $690-$700 million).
The adjusted EBITDA forecast has been updated to $470-$480 million (earlier $455-$475 million).
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in fresh estimates.
The consensus estimate has shifted -101.14% due to these changes.
VGM Scores
Currently, Exact Sciences has a strong Growth Score of A, though it is lagging a lot on the Momentum Score front with an F. Charting a somewhat similar path, the stock has a score of D on the value side, putting it in the bottom 40% for value investors.
Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Exact Sciences has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Exact Sciences belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Repligen (RGEN - Free Report) , has gained 12.3% over the past month. More than a month has passed since the company reported results for the quarter ended September 2025.
Repligen reported revenues of $188.8 million in the last reported quarter, representing a year-over-year change of +21.9%. EPS of $0.46 for the same period compares with $0.43 a year ago.
Repligen is expected to post earnings of $0.44 per share for the current quarter, representing no change from the year-ago quarter. Over the last 30 days, the Zacks Consensus Estimate has changed +0.5%.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Repligen. Also, the stock has a VGM Score of D.